MSD’s oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor has reduced low-density lipoprotein cholesterol (LDL-C) levels when combined with background therapies ...
Boston presented the pair of trial readouts at the 2026 American College of Cardiology (ACC) conference in New Orleans.
The analysis supports making dapagliflozin part of standard inpatient heart failure (HF) pathways rather than postponing it until discharge.
Idorsia has reported positive top-line data from its Phase II dose-finding trial evaluating daridorexant for paediatric insomnia disorder.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results